TCL1A and B-cell chronic lymphocytic leukemia: With that in mind, we used the two corresponding models: (1) Eμ-Myc30, where the c-Myc oncogene is placed under the control of the immunoglobulin enhancer to induce a highly aggressive B-lymphoid malignancy, and (2) Eμ-TCL131, where the TCL1 oncogene is driven by the immunoglobulin enhancer and represents a well-established model of CLL.